Free Trial
NASDAQ:ETNB

89bio Q4 2024 Earnings Report

89bio logo
$9.65 +0.04 (+0.42%)
Closing price 04:00 PM Eastern
Extended Trading
$9.65 +0.00 (+0.05%)
As of 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

89bio EPS Results

Actual EPS
-$1.02
Consensus EPS
-$0.60
Beat/Miss
Missed by -$0.42
One Year Ago EPS
N/A

89bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

89bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, February 27, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

89bio's Q2 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

89bio Earnings Headlines

Is Now the Time to Buy Biotech Stocks?
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More 89bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 89bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89bio and other key companies, straight to your email.

About 89bio

89bio (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

View 89bio Profile

More Earnings Resources from MarketBeat